Sioux Falls Community Cancer Consortium-Clinical Cancer Oncology Program is a multidisciplinary group of private practitioners dedicated to producing high quality clinical cancer research in a community setting. The potential for future outstanding performance as a community clinical oncology program is demonstrated by past and present achievements in clinical cancer research, local cancer control activities, and medical education at all levels in the face of difficult financial circumstances. SFCCC has a well-established, productive relationship with our research base, The Mayo Clinic. This relationship started in 1977 when Central Plains Clinic became a charter member of the NCCTG. Since then the Sioux Falls medical community has generated clinical cancer research data of unexcelled quality and placed large numbers of community patients on high priority, nationally approved clinical cancer research protocols. SFCCC-CCOP is the only source in the Sioux Falls community and regional referral area established to bring the benefits of the national cancer program to a large segment of this area's referral population. The SFCCC organization has earned a CCOP award by virtue of its record of sacrifice, effort and accomplishment in terms of clinical cancer research and local cancer control programs. SFCCC-CCOP will obtain advisory and statistical coordination through its primary rsearch base cooperative agreement with the Mayo Clinic. This relationship will be enhanced by NCCTG and MCCC acting as intermediary for an affiliation with ECOG and CCSG. Specific objectives of this application include further development and availability of community based clinical cancer research to patients in E. South Dakota, SW Minnesota, and NW Iowa. Such a mechanism will enhance the participation of patients in nationally-approved clinical cancer research protocols. The project will also speed the transfer of newly-developed cancer-related technologies and cancer control projects to reduce regional cancer mortality through widespread community applications. The approval of the SFCCC-CCOP will establish an excellent foundation for the participation of the Sioux Falls regional referral area in future cancer control and prevention research activities. We predict confidently, on the basis of our proven past performance, that SFCCC-CCOP will enter at least 175 patients per year on the research protocols provided through these research bases.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA035103-03S1
Application #
3557491
Study Section
(SRC)
Project Start
1983-09-19
Project End
1987-05-31
Budget Start
1985-09-01
Budget End
1987-05-31
Support Year
3
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of South Dakota
Department
Type
Schools of Medicine
DUNS #
929930808
City
Vermillion
State
SD
Country
United States
Zip Code
57069
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Schneider, Bryan P; O'Neill, Anne; Shen, Fei et al. (2015) Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). Br J Cancer 113:1651-7
Liu, Heshan; Tan, Angelina D; Qin, Rui et al. (2015) Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients. SOJ Anesthesiol Pain Manag 2:
Wagner-Johnston, Nina D; Sloan, Jeff A; Liu, Heshan et al. (2015) 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. Cancer 121:2537-43

Showing the most recent 10 out of 72 publications